SG11201908911QA - Modified mri contrast agents and uses thereof - Google Patents

Modified mri contrast agents and uses thereof

Info

Publication number
SG11201908911QA
SG11201908911QA SG11201908911QA SG11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA SG 11201908911Q A SG11201908911Q A SG 11201908911QA
Authority
SG
Singapore
Prior art keywords
california
international
san diego
contrast agents
mri contrast
Prior art date
Application number
Inventor
Clare L M Leguyader
Nathan C Gianneschi
Cassandra E Callmann
Matthew P Thompson
Treffly Ditri
Paul A Bertin
Original Assignee
Univ California
Vybyl Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Vybyl Holdings Inc filed Critical Univ California
Publication of SG11201908911QA publication Critical patent/SG11201908911QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/06Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10Organic compounds
    • A61K49/101Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals
    • A61K49/106Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA
    • A61K49/108Organic compounds the carrier being a complex-forming compound able to form MRI-active complexes with paramagnetic metals the complex-forming compound being cyclic, e.g. DOTA the metal complex being Gd-DOTA
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Radiology & Medical Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 01 November 2018 (01.11.2018) WIPO I PCT o n ono o onno (10) International Publication Number WO 2018/200615 A2 (51) International Patent Classification: A61K 49/10 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2018/029271 (22) International Filing Date: 25 April 2018 (25.04.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/491,159 27 April 2017 (27.04.2017) US (71) Applicants: THE REGENTS OF THE UNIVERSI- TY OF CALIFORNIA [US/US]; 1111 Franklin Street, 5th Floor, Oakland, California 94607 (US). VY- BYL HOLDINGS, INC. [US/US]; 2501 Davey Road, Woodridge, Illinois 60517 (US). (72) Inventors: LEGUYADER, Clare L. M.; 10300 N. Tor- rey Pines Rd., San Diego, California 92037 (US). GIAN- NESCHI, Nathan C.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). CALLMANN, Cassandra E.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). THOMPSON, Matthew P.; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). DITRI, Treffly; 10300 N. Torrey Pines Rd., San Diego, California 92037 (US). BERTIN, Paul A.; 2501 Davey Rd., Woodridge, Illi- nois 60517 (US). (74) Agent: DAILEY, Robert S.; Kilpatrick Townsend & Stockton LLP, 1001 W. 4th St., Winston Salem, North Car- olina 27101 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: without international search report and to be republished upon receipt of that report (Rule 48.2(g)) = (54) Title: MODIFIED MRI CONTRAST AGENTS AND USES THEREOF N O O 00 O O FIG. 1 (57) : The present disclosure generally provides compounds useful as MRI contrast agents. In some aspects, the disclosure provides MRI contrast agents that are chemically modified to have one or more moieties that include hydrophobic portions. In some aspects, the disclosure provides compositions that include such modified MRI contrast agents and a protein, such as albumin or albumin mimetics. Further, the disclosure provides various uses of these compounds and compositions.
SG11201908911Q 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof SG11201908911QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762491159P 2017-04-27 2017-04-27
PCT/US2018/029271 WO2018200615A2 (en) 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof

Publications (1)

Publication Number Publication Date
SG11201908911QA true SG11201908911QA (en) 2019-11-28

Family

ID=63920047

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201908911Q SG11201908911QA (en) 2017-04-27 2018-04-25 Modified mri contrast agents and uses thereof

Country Status (9)

Country Link
US (1) US20200046859A1 (en)
EP (1) EP3615088A4 (en)
JP (1) JP2020517584A (en)
KR (1) KR20190135500A (en)
CN (1) CN110582306A (en)
AU (1) AU2018258345A1 (en)
CA (1) CA3057976A1 (en)
SG (1) SG11201908911QA (en)
WO (1) WO2018200615A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10023581B2 (en) * 2015-09-22 2018-07-17 The Regents Of The University Of California Modified cytotoxins and their therapeutic use

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4011684A1 (en) * 1990-04-06 1991-10-10 Schering Ag DTPA MONOAMIDES, PHARMACEUTICAL AGENTS CONTAINING THESE COMPOUNDS, THEIR USE AND METHOD FOR THE PRODUCTION THEREOF
JP3404787B2 (en) * 1993-03-12 2003-05-12 三菱ウェルファーマ株式会社 Novel diethylenetriaminepentaacetic acid derivative, complex compound of the derivative with a metal atom, and diagnostic agent containing the complex compound
PT907379E (en) * 1996-04-01 2004-09-30 Epix Medical Inc BIOACTIVATED CONTRACT AGENTS FOR DIAGNOSTIC IMAGIOLOGY
DE19652387A1 (en) * 1996-12-04 1998-06-10 Schering Ag Macrocyclic metal complex carboxylic acids, their use and processes for their preparation
WO2002080757A2 (en) * 2001-04-04 2002-10-17 Metaprobe, Inc. Novel functional agents for magnetic resonance imaging
EP1864968A4 (en) * 2005-03-09 2011-04-27 Japan Science & Tech Agency Complex compound and mri probe made of same
WO2008144728A1 (en) * 2007-05-21 2008-11-27 Bracco Imaging S.P.A. Conjugates which bind a blood protein such as human serum albumin and methods of using the same in diagnostic and therapeutic applications

Also Published As

Publication number Publication date
EP3615088A4 (en) 2021-01-27
JP2020517584A (en) 2020-06-18
US20200046859A1 (en) 2020-02-13
AU2018258345A1 (en) 2019-10-17
CA3057976A1 (en) 2018-11-01
WO2018200615A2 (en) 2018-11-01
WO2018200615A3 (en) 2019-01-10
EP3615088A2 (en) 2020-03-04
CN110582306A (en) 2019-12-17
KR20190135500A (en) 2019-12-06

Similar Documents

Publication Publication Date Title
SG11201811432WA (en) Rna for cancer therapy
SG11201909949XA (en) Targeted immunotolerance
SG11201908179UA (en) Aryl cyclopropyl-amino-isoquinolinyl amide compounds
SG11201809082WA (en) Nlrp3 modulators
SG11201903867YA (en) Antibodies directed against t cell immunoglobulin and mucin protein 3 (tim-3)
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201805645QA (en) Lsd1 inhibitors
SG11201808682XA (en) Silicone atoms containing ivacaftor analogues
SG11201804506RA (en) Systems and methods for rendering multiple levels of detail
SG11201808990QA (en) Compositions for topical application of compounds
SG11201807025SA (en) Crispr/cas systems for c-1 fixing bacteria
SG11201807279QA (en) Binding proteins and methods of use thereof
SG11201811643TA (en) Compounds and methods for modulating rna function
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201907023UA (en) Method of reducing neutropenia
SG11201807421TA (en) The use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
SG11201407343XA (en) Subfamily e simian adenoviruses a1302, a1320, a1331 and a1337 and uses thereof
SG11201809751XA (en) Egfr inhibitor compounds
SG11201805149XA (en) Compositions comprising 15-hepe and methods of using the same
SG11201808676RA (en) Methods of treating pediatric cancers
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201804412SA (en) Dimeric contrast agents
SG11201906973TA (en) Multiple transgene recombinant adenovirus
SG11201909837YA (en) Methods for treating lung disorders
SG11201908114UA (en) Pyrimidopyrimidinones useful as wee-1 kinase inhibitors